

Staar Surgical Co. (STAA)

Nasdaq; healthcare; SIC 3851, Ophthalmic Goods; CIK 0000718937

Staar Surgical Co. STAA; healthcare	
Grade	B A B C D E second fifth of 371 graded peers percentile 29.2; sampling error 2.5 points; lower is stronger
Rank	109 of 371
Profitability	C percentile 50.7
Solvency	B percentile 28.2
Growth and financing	C percentile 44.6
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$451.7M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: fortress balance sheet
Inputs computable	9 of 14
Graded from	filings received through Mar 3, 2026 220 days before the rescans; latest periodic filing 10-Q received Aug 12, 2026
Last close	\$22.38 2026-10-08; market equity \$1.1B
Price used in grade	None



B, the elk
second fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: A from Mar 21, 2024, B from Feb 21, 2025, A/B from Mar 21, 2025

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 3, 2026

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or "refractive" surgery. We have been dedicated solely to ophthalmic surgery for over 40 years. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact

lenses while achieving excellent visual acuity through refractive vision correction.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 50.7						
Gross profitability		40.4%	32.2%	32.1	372	2026-01-02
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(9.6%)	(6.6%)	42.5	811	2026-01-02
Gross margin stability, five years		6.5 pts	2.8 pts	77.7	243	2026-01-02
Solvency, sleeve percentile 28.2						
Twelve-month failure probability		0.04%	0.07%	23.5	248	2026-07-03
Altman Z double-prime		4.46	(0.31)	20.7	756	2026-01-02
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2017-12-29; latest annual assets end 2026-01-02
Current ratio		4.55x	2.96x	40.5	839	2026-01-02
Growth and financing, sleeve percentile 44.6						
Revenue growth, three-year compound		0.0%	10.0%	71.0	415	2026-01-02
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		2.5%	2.1%	45.5	704	2026-01-02
Net share issuance, one year		0.4%	2.5%	17.2	634	2026-02-27

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
104	Agape ATP Corp. (ATPC)	27.8	B	late filer

105	Agios Pharmaceuticals, Inc. (AGIO)	28.1	B	short runway
106	Myriad Genetics Inc. (MYGN)	28.4	B	fortress
				balance sheet
107	DocGo Inc. (DCGO)	28.6	B	late filer,
				fortress
				balance sheet
108	Healthcare Services Group Inc. (HCSG)	28.9	B	
109	Staar Surgical Co. (STAA) <	29.2	B	
110	Cytokinetics Inc. (CYTK)	29.5	B	short runway
111	Steris plc (STE)	29.7	B	
112	Cadre Holdings, Inc. (CDRE)	30.0	B	
113	MSA Safety Inc. (MSA)	30.3	B	
114	BioNexus Gene Lab Corp. (BGLC)	30.5	B	dilution, late
				filer

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(15.9%)	8.0%	33
Distance from 52-week high	(32.9%)	(31.4%)	47
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(3.6%)	(1.0%)	43
Book value to price	0.33	0.28	54
Sales to price	0.21	0.31	40
Composite equity issuance, five years	7.4%	20.3%	36
Relative strength against the sector, log excess return	(0.39)	(0.14)	33

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-01-02	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$148.6M
Operating cash flow, four quarters	-\$3.3M
Months of runway	548.3
Days since last periodic filing	58 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	\$18.5M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$182.4M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
2	assets	us-gaap:Assets	\$451.7M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
3	net income	us-gaap:NetIncomeLoss	-\$80.4M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$34.2M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
5	assets	us-gaap:Assets	\$509.5M	2024-12-27	2026-03-03	10-K	0000718937-26-000004
6	revenue	us-gaap:Revenues	\$239.4M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
7	gross profit	us-gaap:GrossProfit	\$239.6M	2024-12-27	2026-03-03	10-K	0000718937-26-000004

8	revenue	us-gaap:Revenues	\$313.9M	2024-12-27	2026-03-03	10-K	0000718937-26-000004
9	gross profit	us-gaap:GrossProfit	\$252.7M	2023-12-29	2026-03-03	10-K	0000718937-26-000004
10	revenue	us-gaap:Revenues	\$322.4M	2023-12-29	2026-03-03	10-K	0000718937-26-000004
11	gross profit	us-gaap:GrossProfit	\$223.4M	2022-12-30	2025-02-21	10-K	0000950170-25-024813
12	revenue	us-gaap:Revenues	\$239.4M	2022-12-30	2026-03-03	10-K	0000718937-26-000004
13	gross profit	us-gaap:GrossProfit	\$178.6M	2021-12-31	2024-02-27	10-K	0000950170-24-020572
14	revenue	us-gaap:Revenues	\$230.5M	2021-12-31	2024-02-27	10-K	0000950170-24-020572
15	current assets	us-gaap:AssetsCurrent	\$311.5M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
16	current liabilities	us-gaap:LiabilitiesCurrent	\$68.5M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$148.0M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
18	operating income	us-gaap:OperatingIncomeLoss	-\$91.7M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
19	book equity	us-gaap:StockholdersEquity	\$344.2M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
20	liabilities	us-gaap:Liabilities	\$107.5M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
21	operating income	us-gaap:OperatingIncomeLoss	-\$3.6M	2017-12-29	2020-02-26	10-K	0001564590-20-006791
22	interest expense	us-gaap:InterestExpense	\$112,000	2017-12-29	2018-02-28	10-K	0001144204-18-011838
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$5.8M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$15.7M	2024-12-27	2026-03-03	10-K	0000718937-26-000004
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$23.4M	2024-12-27	2026-03-03	10-K	0000718937-26-000004
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$14.6M	2023-12-29	2026-03-03	10-K	0000718937-26-000004
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$18.2M	2023-12-29	2026-03-03	10-K	0000718937-26-000004
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$35.7M	2022-12-30	2025-02-21	10-K	0000950170-25-024813
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$18.1M	2022-12-30	2025-02-21	10-K	0000950170-25-024813
30	depreciation amortization	us-gaap:Depreciation	\$8.3M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$34.1M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
32	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$1.8M	2026-01-02	2026-03-03	10-K	0000718937-26-000004
33	current assets	us-gaap:AssetsCurrent	\$367.9M	2024-12-27	2026-03-03	10-K	0000718937-26-000004
34	current liabilities	us-gaap:LiabilitiesCurrent	\$70.3M	2024-12-27	2026-03-03	10-K	0000718937-26-000004
35	assets	us-gaap:Assets	\$488.7M	2023-12-29	2025-02-21	10-K	0000950170-25-024813
36	assets	us-gaap:Assets	\$418.8M	2022-12-30	2024-02-27	10-K	0000950170-24-020572
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,512,749	2026-02-27	2026-03-03	10-K	0000718937-26-000004
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,325,372	2025-02-18	2025-02-21	10-K	0000950170-25-024813